Drugs / SYR-322MET
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT02508168 | Apr 2016 | — | Takeda | Completed | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | SYR-322MET | ClinicalTrials.gov intervention name — accepted as the source's own label NCT02508168 ↗ |
| Known as | Vipdomet | “fixed-dose combination tablet Vipdomet (Alogliptin FDC With Metformin)” NCT02508168 ↗ |
| Route | Oral | “SYR-322MET (alogliptin 12.5 mg and metformin 1000 mg) fixed-dose combination (FDC) tablets, orally, once” NCT02508168 ↗ |